Hubei Vanz Pharm Co.,Ltd
Diamond Supplier Enterprise Certification
- Diamond
Supplier - 5th
years
Diamond Supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: 86-27-84492310
Tel: 008618986076206
Tel: +86 27 84492310
Tel: WhatsApp +8615927784577
Tel: +8618071739296
Mobile:
Tel: 86-27-84492310
Fax: 86-27-84402310
URL: http://www.vanzpharm.com/en/index.html
Province/state: Hubei
City: JIAYU
Street: FANHU INDUSTRY PARK
MaxCard:
Ms.Bella Li Ms.Chelsea GaoCAS NO.1208319-27-0
cas 1208319-27-0 Oclacitinib Maleate(PF-03394197) powder
| Product Name: | Oclacitinib Maleate(PF-03394197) |
| CAS: | 1208319-27-0 |
| MF: | C19H27N5O6S |
| MW: | 453.51 |
What is oclacitinib maleate
oclacitinib maleate inhibitor to be developed for dogs. It was recently approved for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. In recent years, there has been a significant evolution in understanding regarding the pathophysiology of allergic and atopic diseases. The molecular mechanisms involved in stimulating the itch response have been elaborated (Marsella et al., 2012), and it is now understood that cytokines play a key role in initiating the neuronal itch stimulation which triggers pruritic behavior (scratching, rubbing, chewing, etc.) in dogs. This leads to the establishment of a vicious cycle of itch that exacerbates skin lesions and amplifies defects in the skin barrier function in clinically affected dogs.
Oclacitinib function
Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. It is considered to be highly effective in dogs, and has been established as safe for at least short-term use. Its efficacy equals that of prednisolone at first, though oclacitinib has been found to be more effective in the short term in terms of itchiness and dermatitis, long term safety is unknown. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. While safe in the short term, oclacitinib's long-term safety is unknown. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis.